Share on StockTwits

Equities researchers at Needham & Company LLC raised their target price on shares of Hologic (NASDAQ:HOLX) to $30.00 in a research report issued on Wednesday. Needham & Company LLC’s price target points to a potential upside of 19.33% from the company’s current price.

Other equities research analysts have also recently issued reports about the stock. Analysts at Argus raised their price target on shares of Hologic from $27.00 to $31.00 in a research note on Monday, May 12th. They now have a “buy” rating on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Hologic in a research note on Thursday, May 1st. They now have a $28.00 price target on the stock. Finally, analysts at RBC Capital raised their price target on shares of Hologic from $21.00 to $22.00 in a research note on Thursday, May 1st. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $23.61.

Hologic (NASDAQ:HOLX) opened at 25.14 on Wednesday. Hologic has a 1-year low of $18.46 and a 1-year high of $25.84. The stock’s 50-day moving average is $24.45 and its 200-day moving average is $22.36. The company’s market cap is $6.947 billion.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, April 30th. The company reported $0.37 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.33 by $0.04. The company had revenue of $625.00 million for the quarter, compared to the consensus estimate of $609.35 million. On average, analysts predict that Hologic will post $1.40 earnings per share for the current fiscal year.

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products to serving the healthcare needs of women.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.